Prediction of Bleeding Complications After Atrial Fibrillation Ablation Utilizing Platelet-Fibrin Clot Strength and Platelet Aeactivity
Objective
To determine whether platelet-fibrin clot strength (PFCS) using thromboelastography and platelet reactivity assays can predict the risk of post-procedural bleeding in patients undergoing atrial fibrillation ablation.
Eligibility
Key Inclusion Criteria:
- Age >18 yr old
- History of atrial fibrillation
- Undergoing PFA atrial fibrillation ablation with Vascade MVP venous closure device
Key Exclusion Criteria:
- Pregnant/nursing
- Unable to provide consent
- Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;
- Known significant coagulopathy/bleeding disorder such as thrombocytopenia (platelet count <100,000/mm³), thrombasthenia, hemophilia, von Willebrand’s disease or anemia (Hemoglobin <10g/dL, Hematocrit <30%);
- Previous vascular grafts or surgery at the target vessel access site;
- Symptomatic ipsilateral lower extremity ischemia